Treatment-emergent adverse events during induction (cycles 1-8; N = 53)
| . | Any grade, n (%) . | Grade 3/4, n (%) . |
|---|---|---|
| Nonhematologic | ||
| Hyperglycemia | 38 (72) | 12 (23) |
| Edema | 25 (47) | 2 (4) |
| Hypophosphatemia | 24 (45) | 13 (25) |
| Fatigue | 20 (38) | 1 (2) |
| Muscle cramping | 17 (32) | 0 (0) |
| Rash | 15 (28) | 4 (8) |
| Elevated liver function test | 15 (28) | 4 (8) |
| Diarrhea | 14 (26) | 0 (0) |
| Infection* | 12 (23) | 2 (4) |
| Phlebitis | 12 (23) | 0 (0) |
| Peripheral neuropathy | 12 (23)† | 0 (0) |
| Dyspnea | 8 (15) | 2 (4) |
| Deep vein thrombosis | 6 (11) | 2 (4) |
| Pulmonary embolism | 3 (6) | 3 (6) |
| Nausea | 7 (13) | 0 (0) |
| Renal | 5 (9) | 1 (2) |
| Constipation | 5 (9) | 0 (0) |
| Mood alterations | 5 (9) | 1 (2) |
| Hematologic | ||
| Thrombocytopenia | 36 (68) | 9 (17) |
| Anemia | 32 (60) | 11 (21) |
| Neutropenia | 16 (30) | 9 (17) |
| . | Any grade, n (%) . | Grade 3/4, n (%) . |
|---|---|---|
| Nonhematologic | ||
| Hyperglycemia | 38 (72) | 12 (23) |
| Edema | 25 (47) | 2 (4) |
| Hypophosphatemia | 24 (45) | 13 (25) |
| Fatigue | 20 (38) | 1 (2) |
| Muscle cramping | 17 (32) | 0 (0) |
| Rash | 15 (28) | 4 (8) |
| Elevated liver function test | 15 (28) | 4 (8) |
| Diarrhea | 14 (26) | 0 (0) |
| Infection* | 12 (23) | 2 (4) |
| Phlebitis | 12 (23) | 0 (0) |
| Peripheral neuropathy | 12 (23)† | 0 (0) |
| Dyspnea | 8 (15) | 2 (4) |
| Deep vein thrombosis | 6 (11) | 2 (4) |
| Pulmonary embolism | 3 (6) | 3 (6) |
| Nausea | 7 (13) | 0 (0) |
| Renal | 5 (9) | 1 (2) |
| Constipation | 5 (9) | 0 (0) |
| Mood alterations | 5 (9) | 1 (2) |
| Hematologic | ||
| Thrombocytopenia | 36 (68) | 9 (17) |
| Anemia | 32 (60) | 11 (21) |
| Neutropenia | 16 (30) | 9 (17) |